Search results
US FDA approves Merck's pneumococcal vaccine for adults
Reuters· 2 hours ago, opens new tab said on Monday the U.S. Food and Drug Administration has approved its...
Milestone for Biotest: US Approval for Innovative Immunoglobulin Yimmugo
NewMediaWire via Yahoo Finance· 4 hours agoFDA approval secures significant future sales and earnings growth through entry into the world's...
FDA grants approval for Bristol Myers Squibb’s Augtyro for solid tumours
Pharmaceutical Technology via Yahoo Finance· 17 hours agoThe trial assessed the drug's efficacy in adults with NTRK-positive solid tumours, demonstrating...
FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
Medical Xpress· 10 hours agoThe risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared...
What Does FDA's Draft Platform Guidance Mean For CGT Companies?
BioresearchOnline· 17 hours agoThe U.S. FDA released the much-anticipated draft guidance Platform Technology Designation Program...
US FDA Approves Merck's Pneumococcal Vaccine for Adults
US News & World Report· 2 hours agoThe disease can lead to infections in several parts of the body including the lungs, where they can cause pneumonia. Merck's vaccine, branded Capvaxive, helped produce an ...
AstraZeneca/Fibrogen’s Roxadustat FDA Review Further Delayed Following Unanticipated Advisory...
Clinical Trials Arena via Yahoo Finance· 18 hours agoFDA Delays Decision on AstraZeneca/Fibrogen’s Roxadustat for CKD Anemia On March 1, AstraZeneca and...
Microdose mushroom chocolates have hospitalized people in 8 states, FDA warns
USA TODAY via Yahoo News· 7 hours agoHealth officials are again warning people not to consume a brand of microdosing mushroom-infused...
AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
Zacks via Yahoo Finance· 8 hours agoThe FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch...
FDA Panel Votes Against MDMA-Assisted Talk Therapy | JD Supra
JD Supra· 5 hours agoOn June 4, 2024, a panel of experts advising the Food and Drug Administration (FDA) on the use of the psychedelic midomafetamine (MDMA) for post-traumatic stress disorder ...